Microsomal epoxide hydrolase polymorphisms and lung cancer risk

A quantitative review

Won Jin Lee, Paul Brennan, Paolo Boffetta, Stephanie J. London, Simone Benhamou, Agneta Rannug, Jordi To-Figueras, Magnus Ingelman-Sundberg, Peter Shields, Laura Gaspari, Emanuela Taioli

Research output: Contribution to journalReview article

63 Citations (Scopus)

Abstract

To investigate the role of microsomal epoxide hydrolase (mEH) polymorphisms in the aetiology of lung cancer and to assess the interaction between mEH polymorphisms and smoking, we performed a meta-analysis of seven published studies, which included 2078 cases and 3081 controls, and a pooled analysis of eight studies (four published and four unpublished at that time) with a total of 986 cases and 1633 controls. The combined meta-analysis odds ratios (ORs) were 0.98 (95% confidence interval [CI] = 0.72-1.35) for polymorphism at amino acid 113 in exon 3 (His/His versus Tyr/Tyr genotype) and 1.00 (95% CI = 0.71-1.41) for polymorphism at amino acid 139 in exon 4 (Arg/Arg versus His/His genotype). In the pooled analysis, we observed a significant decrease in lung cancer risk (OR = 0.70, 95% CI = 0.51-0.96) for exon 3 His/His genotype after adjustment for age, sex, smoking and centre. The protective effect of exon 3 polymorphism seems stronger for adenocarcinoma of the lung than for other histological types. The OR for high predicted mEH activity, compared with low activity, was 1.54 (95% CI = 0.77-3.07) in the meta analysis and 1.18 (95% CI = 0.92-1.52) in the pooled analysis. We did not find a consistent modification of the carcinogenic effect of smoking according to mEH polymorphism, although the risk of lung cancer decreased among never smokers with high mEH activity and among heavy smokers with the exon 3 His/His genotype. In conclusion, this study suggests a possible effect of mEH polymorphisms at exon 3 in modulating lung cancer. If present, this effect may vary among different populations, possibly because of interaction with genetic or environmental factors.

Original languageEnglish
Pages (from-to)230-241
Number of pages12
JournalBiomarkers
Volume7
Issue number3
DOIs
Publication statusPublished - 2002 Jul 4
Externally publishedYes

Fingerprint

Epoxide Hydrolases
Polymorphism
Exons
Lung Neoplasms
Confidence Intervals
Odds Ratio
Genotype
Meta-Analysis
Smoking
Amino Acids
Population

Keywords

  • Lung cancer
  • Microsomal epoxide hydrolase
  • Polymorphism
  • Smoking

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Cite this

Lee, W. J., Brennan, P., Boffetta, P., London, S. J., Benhamou, S., Rannug, A., ... Taioli, E. (2002). Microsomal epoxide hydrolase polymorphisms and lung cancer risk: A quantitative review. Biomarkers, 7(3), 230-241. https://doi.org/10.1080/13547500210121882

Microsomal epoxide hydrolase polymorphisms and lung cancer risk : A quantitative review. / Lee, Won Jin; Brennan, Paul; Boffetta, Paolo; London, Stephanie J.; Benhamou, Simone; Rannug, Agneta; To-Figueras, Jordi; Ingelman-Sundberg, Magnus; Shields, Peter; Gaspari, Laura; Taioli, Emanuela.

In: Biomarkers, Vol. 7, No. 3, 04.07.2002, p. 230-241.

Research output: Contribution to journalReview article

Lee, WJ, Brennan, P, Boffetta, P, London, SJ, Benhamou, S, Rannug, A, To-Figueras, J, Ingelman-Sundberg, M, Shields, P, Gaspari, L & Taioli, E 2002, 'Microsomal epoxide hydrolase polymorphisms and lung cancer risk: A quantitative review', Biomarkers, vol. 7, no. 3, pp. 230-241. https://doi.org/10.1080/13547500210121882
Lee, Won Jin ; Brennan, Paul ; Boffetta, Paolo ; London, Stephanie J. ; Benhamou, Simone ; Rannug, Agneta ; To-Figueras, Jordi ; Ingelman-Sundberg, Magnus ; Shields, Peter ; Gaspari, Laura ; Taioli, Emanuela. / Microsomal epoxide hydrolase polymorphisms and lung cancer risk : A quantitative review. In: Biomarkers. 2002 ; Vol. 7, No. 3. pp. 230-241.
@article{ffe01b6863df41a185eae3b451fc9968,
title = "Microsomal epoxide hydrolase polymorphisms and lung cancer risk: A quantitative review",
abstract = "To investigate the role of microsomal epoxide hydrolase (mEH) polymorphisms in the aetiology of lung cancer and to assess the interaction between mEH polymorphisms and smoking, we performed a meta-analysis of seven published studies, which included 2078 cases and 3081 controls, and a pooled analysis of eight studies (four published and four unpublished at that time) with a total of 986 cases and 1633 controls. The combined meta-analysis odds ratios (ORs) were 0.98 (95{\%} confidence interval [CI] = 0.72-1.35) for polymorphism at amino acid 113 in exon 3 (His/His versus Tyr/Tyr genotype) and 1.00 (95{\%} CI = 0.71-1.41) for polymorphism at amino acid 139 in exon 4 (Arg/Arg versus His/His genotype). In the pooled analysis, we observed a significant decrease in lung cancer risk (OR = 0.70, 95{\%} CI = 0.51-0.96) for exon 3 His/His genotype after adjustment for age, sex, smoking and centre. The protective effect of exon 3 polymorphism seems stronger for adenocarcinoma of the lung than for other histological types. The OR for high predicted mEH activity, compared with low activity, was 1.54 (95{\%} CI = 0.77-3.07) in the meta analysis and 1.18 (95{\%} CI = 0.92-1.52) in the pooled analysis. We did not find a consistent modification of the carcinogenic effect of smoking according to mEH polymorphism, although the risk of lung cancer decreased among never smokers with high mEH activity and among heavy smokers with the exon 3 His/His genotype. In conclusion, this study suggests a possible effect of mEH polymorphisms at exon 3 in modulating lung cancer. If present, this effect may vary among different populations, possibly because of interaction with genetic or environmental factors.",
keywords = "Lung cancer, Microsomal epoxide hydrolase, Polymorphism, Smoking",
author = "Lee, {Won Jin} and Paul Brennan and Paolo Boffetta and London, {Stephanie J.} and Simone Benhamou and Agneta Rannug and Jordi To-Figueras and Magnus Ingelman-Sundberg and Peter Shields and Laura Gaspari and Emanuela Taioli",
year = "2002",
month = "7",
day = "4",
doi = "10.1080/13547500210121882",
language = "English",
volume = "7",
pages = "230--241",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Microsomal epoxide hydrolase polymorphisms and lung cancer risk

T2 - A quantitative review

AU - Lee, Won Jin

AU - Brennan, Paul

AU - Boffetta, Paolo

AU - London, Stephanie J.

AU - Benhamou, Simone

AU - Rannug, Agneta

AU - To-Figueras, Jordi

AU - Ingelman-Sundberg, Magnus

AU - Shields, Peter

AU - Gaspari, Laura

AU - Taioli, Emanuela

PY - 2002/7/4

Y1 - 2002/7/4

N2 - To investigate the role of microsomal epoxide hydrolase (mEH) polymorphisms in the aetiology of lung cancer and to assess the interaction between mEH polymorphisms and smoking, we performed a meta-analysis of seven published studies, which included 2078 cases and 3081 controls, and a pooled analysis of eight studies (four published and four unpublished at that time) with a total of 986 cases and 1633 controls. The combined meta-analysis odds ratios (ORs) were 0.98 (95% confidence interval [CI] = 0.72-1.35) for polymorphism at amino acid 113 in exon 3 (His/His versus Tyr/Tyr genotype) and 1.00 (95% CI = 0.71-1.41) for polymorphism at amino acid 139 in exon 4 (Arg/Arg versus His/His genotype). In the pooled analysis, we observed a significant decrease in lung cancer risk (OR = 0.70, 95% CI = 0.51-0.96) for exon 3 His/His genotype after adjustment for age, sex, smoking and centre. The protective effect of exon 3 polymorphism seems stronger for adenocarcinoma of the lung than for other histological types. The OR for high predicted mEH activity, compared with low activity, was 1.54 (95% CI = 0.77-3.07) in the meta analysis and 1.18 (95% CI = 0.92-1.52) in the pooled analysis. We did not find a consistent modification of the carcinogenic effect of smoking according to mEH polymorphism, although the risk of lung cancer decreased among never smokers with high mEH activity and among heavy smokers with the exon 3 His/His genotype. In conclusion, this study suggests a possible effect of mEH polymorphisms at exon 3 in modulating lung cancer. If present, this effect may vary among different populations, possibly because of interaction with genetic or environmental factors.

AB - To investigate the role of microsomal epoxide hydrolase (mEH) polymorphisms in the aetiology of lung cancer and to assess the interaction between mEH polymorphisms and smoking, we performed a meta-analysis of seven published studies, which included 2078 cases and 3081 controls, and a pooled analysis of eight studies (four published and four unpublished at that time) with a total of 986 cases and 1633 controls. The combined meta-analysis odds ratios (ORs) were 0.98 (95% confidence interval [CI] = 0.72-1.35) for polymorphism at amino acid 113 in exon 3 (His/His versus Tyr/Tyr genotype) and 1.00 (95% CI = 0.71-1.41) for polymorphism at amino acid 139 in exon 4 (Arg/Arg versus His/His genotype). In the pooled analysis, we observed a significant decrease in lung cancer risk (OR = 0.70, 95% CI = 0.51-0.96) for exon 3 His/His genotype after adjustment for age, sex, smoking and centre. The protective effect of exon 3 polymorphism seems stronger for adenocarcinoma of the lung than for other histological types. The OR for high predicted mEH activity, compared with low activity, was 1.54 (95% CI = 0.77-3.07) in the meta analysis and 1.18 (95% CI = 0.92-1.52) in the pooled analysis. We did not find a consistent modification of the carcinogenic effect of smoking according to mEH polymorphism, although the risk of lung cancer decreased among never smokers with high mEH activity and among heavy smokers with the exon 3 His/His genotype. In conclusion, this study suggests a possible effect of mEH polymorphisms at exon 3 in modulating lung cancer. If present, this effect may vary among different populations, possibly because of interaction with genetic or environmental factors.

KW - Lung cancer

KW - Microsomal epoxide hydrolase

KW - Polymorphism

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=0035992103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035992103&partnerID=8YFLogxK

U2 - 10.1080/13547500210121882

DO - 10.1080/13547500210121882

M3 - Review article

VL - 7

SP - 230

EP - 241

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 3

ER -